- Home
- XAIR vs NXTS Comparison
XAIR vs NXTS Comparison
Compare XAIR & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | NXTS |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Israel |
| Employees | N/A | 9 |
| Industry | Medical/Dental Instruments | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.2M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | XAIR | NXTS |
|---|---|---|
| Price | $0.43 | $3.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 259.8K | ★ 2.4M |
| Earning Date | 06-16-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,679,000.00 | N/A |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 107.26 | N/A |
| 52 Week Low | $0.33 | $0.55 |
| 52 Week High | $3.78 | $23.80 |
Technical Indicators
Market Signals| Indicator | XAIR | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 44.16 |
| Support Level | $0.43 | $0.55 |
| Resistance Level | $0.52 | $5.97 |
| Average True Range (ATR) | 0.05 | 1.52 |
| MACD | 0.00 | -0.30 |
| Stochastic Oscillator | 48.81 | 2.29 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.